Day One Biopharmaceuticals Reports Strong 2025 Financial Results and Growth Outlook
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 24 2026
0mins
Source: Yahoo Finance
- Revenue Growth: In 2025, Day One's OJEMDA net product revenue reached $155.4 million, reflecting a 172% year-over-year increase, indicating strong market demand and widespread adoption by prescribers, with guidance for 2026 projected between $225 million and $250 million.
- Clinical Trial Progress: Three-year data from the FIREFLY-1 trial was presented at the 2025 Society for Neuro-Oncology Annual Meeting, confirming the long-term safety and efficacy of OJEMDA in patients with relapsed or refractory pLGG, thereby enhancing the company's market position in rare cancers.
- R&D Expense Management: Research and development expenses totaled $148.1 million in 2025, significantly down from 2024, demonstrating the company's ability to control costs while still advancing product development and improving overall financial health.
- Strong Cash Position: As of December 31, 2025, Day One reported cash and short-term investments totaling $441.1 million, ensuring sufficient funding for future R&D and market expansion initiatives.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
